Evidence map›Paper›PMID 38105286›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Bernardo Leon Rapoport, Jørn Herrstedt, Rebecca Clark Snow, Venkatraman Radhakrishnan, Mitsue Saito, Rudolph M Navari, Teresa Smit

Open access · hybridAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines: results of a multinational and multicenter survey, part of the THRIVE program.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. TTD expert consensus on emesis in gastric cancer: evidence-based strategies for prevention and treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 5 countries.

Bernardo Leon RapoportThe Medical Oncology Centre of Rosebank, 129 Oxford Road, Johannesburg, South Africa. bernardo.rapoport@up.ac.za.ORCID http://orcid.org/0000-0001-7610-3653
Jørn HerrstedtDepartment of Clinical Oncology, Zealand University Hospital, Roskilde, Denmark.ORCID http://orcid.org/0000-0002-8844-6546
Rebecca Clark SnowOncology Supportive Care Consultant, Overland Park, KS, USA.
Venkatraman RadhakrishnanDepartment of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, India.
Mitsue SaitoDepartment of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1916-4844
Rudolph M NavariWorld Health Organization, Birmingham, AL, USA.
Teresa SmitThe Medical Oncology Centre of Rosebank, 129 Oxford Road, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-5750-8815
The Medical Oncology Centre of Rosebank · ZACancer Institute (WIA) · INHematology Oncology Consultants · USJuntendo University · JPUniversity of Copenhagen · DK

Funding

World Health Organization 001
6 · The paper itself

Abstract

purposeThis review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

methodsA systematic literature search was conducted using PubMed from June 1, 2015, through February 1, 2023.

resultsWe identified 56 references (16 were duplications or invalid), leaving 40 manuscripts for this search. The panel classified level I evidence (three manuscripts) and level II evidence (14 manuscripts). High-dose chemotherapy and stem cell transplant were discussed in four of these manuscripts, and multiple-day chemotherapy treatment in 15. Some manuscripts covered both topics. Additionally, a search for breakthrough nausea and vomiting resulted in 12 "hits." No new relevant studies were identified.

conclusionsThe recommendations for patients receiving high-dose chemotherapy with stem cell transplants and patients undergoing multiple-day cisplatin were updated. For patients receiving high-dose chemotherapy for stem cell transplant, a combination of a 5-HT

Indexed as

AntiemeticsAntineoplastic AgentsAprepitantCisplatinDexamethasoneHumansNauseaOlanzapineSerotoninVomitingAntiemeticsAntineoplastic AgentsAprepitantCisplatinDexamethasoneOlanzapineSerotonin5-HT3 receptor antagonistsBreakthrough nausea and vomitingCINVHigh-dose chemotherapyMultiple-day chemotherapyNK1 receptor antagonists

Identifiers

PMID38105286
PMCPMC10725845
OpenAlexW4389861101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.